Twist Bioscience Corporation (TWST) expected to report EPS of -$1.14 for the current quarter

In the latest session, Twist Bioscience Corporation (NASDAQ: TWST) closed at $14.24 down -4.56% from its previous closing price of $14.92. In other words, the price has decreased by -$0.68 from its previous closing price. On the day, 1265045 shares were traded. TWST stock price reached its highest trading level at $14.77 during the session, while it also had its lowest trading level at $13.58.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



For a deeper understanding of Twist Bioscience Corporation’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.20 and its Current Ratio is at 6.80. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 10 when Cho Dennis bought 10,000 shares for $13.20 per share. The transaction valued at 132,000 led to the insider holds 29,297 shares of the business.

Starovasnik Melissa A. sold 1,732 shares of TWST for $45,820 on Feb 09. The Director now owns 11,340 shares after completing the transaction at $26.45 per share. On Feb 09, another insider, JOHANNESSEN JAN, who serves as the Director of the company, sold 1,732 shares for $26.45 each. As a result, the insider received 45,820 and left with 11,616 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TWST now has a Market Capitalization of 732.90M and an Enterprise Value of 388.17M. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.59 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 1.70 whereas that against EBITDA is -1.83.

Stock Price History:

The Beta on a monthly basis for TWST is 1.15, which has changed by -58.99% over the last 52 weeks, in comparison to a change of 1.41% over the same period for the S&P500. Over the past 52 weeks, TWST has reached a high of $58.76, while it has fallen to a 52-week low of $11.46. The 50-Day Moving Average of the stock is 14.03, while the 200-Day Moving Average is calculated to be 26.36.

Shares Statistics:

For the past three months, TWST has traded an average of 1.40M shares per day and 1.42M over the past ten days. A total of 56.78M shares are outstanding, with a floating share count of 56.00M. Insiders hold about 1.00% of the company’s shares, while institutions hold 109.36% stake in the company. Shares short for TWST as of Apr 27, 2023 were 12.37M with a Short Ratio of 12.37M, compared to 11.92M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 21.75% and a Short% of Float of 24.93%.

Earnings Estimates

There are 8 different market analysts currently analyzing its stock. On average, analysts expect EPS of -$1.14 for the current quarter, with a high estimate of -$1.02 and a low estimate of -$1.23, while EPS last year was -$1.08. The consensus estimate for the next quarter is -$1.04, with high estimates of -$0.97 and low estimates of -$1.12.

Analysts are recommending an EPS of between -$3.79 and -$4.48 for the fiscal current year, implying an average EPS of -$4. EPS for the following year is -$3.14, with 8 analysts recommending between -$2.66 and -$3.66.

Revenue Estimates

A total of 7 analysts believe the company’s revenue will be $60.54M this quarter.It ranges from a high estimate of $61M to a low estimate of $60M. As of the current estimate, Twist Bioscience Corporation’s year-ago sales were $56.11M, an estimated increase of 7.90% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $62.25M, an increase of 8.60% over than the figure of $7.90% in the same quarter last year. There is a high estimate of $63.4M for the next quarter, whereas the lowest estimate is $61.63M.

A total of 8 analysts have provided revenue estimates for TWST’s current fiscal year. The highest revenue estimate was $238.7M, while the lowest revenue estimate was $236.3M, resulting in an average revenue estimate of $237.19M. In the same quarter a year ago, actual revenue was $203.56M, up 16.50% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $294.87M in the next fiscal year. The high estimate is $323M and the low estimate is $274M. The average revenue growth estimate for next year is up 24.30% from the average revenue estimate for this year.